Physician profile
Christopher E Kassar
NPI 1346659174
$4,515.32
in general payments reported to CMS, 2019-2025
39 companies · $706 in 2025
The $706 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $546 · 2021: $441 · 2022: $743 · 2023: $627 · 2024: $742 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $660.69 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amarin Pharma, INC. | $502.19 | 2019-2022 | |
| Amgen INC. | $475.37 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $330.72 | 2019-2025 | |
| Abbvie INC. | $310.47 | 2021-2025 | |
| Novo Nordisk INC | $304.35 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.54 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $177.15 | 2021-2025 | Nexletol |
| Astellas Pharma US INC | $159.38 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $145.22 | 2022-2025 | |
| Sanofi Pasteur INC. | $109.34 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $106.71 | 2020-2025 | M-M-R II, Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $95.63 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.08 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $87.93 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kassar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.